Methods for generation of antibodies
View Patent ↗This invention generally relates to methods for the production of antibody producing cells and antibodies in protooncogene expressing animals. The invention also relates to methods for the efficient production of antibodies specific for antigens that are normally subject to immunological constraints such as self tolerance. The invention further relates to the production of antibody producing cells and antibodies without the need for the conventional fusing of antibody producing B cells with a myeloma fusion partner.
1. A method for producing an antibody to an antigen comprising:
a) providing a non-human mammal that inducibly overexpresses MYC, wherein the non-human mammal was produced by
transferring a mammalian hematopoietic stem cell into the non-human mammal, wherein the mammalian hematopoietic stem cell comprises a recombinant nucleic acid molecule encoding an inducible MYC and a recombinant nucleic acid molecule encoding an antigen, and wherein the non-human mammal was lethally-irradiated or sub lethally-irradiated prior to having the hematopoietic stem cell transferred into the non-human mammal;
b) inducing the overexpression of MYC in the non-human-mammal after formation of mature B cells from the transferred mammalian hematopoietic stem cell;
c) recovering a B cell overexpressing MYC from the non-human mammal, wherein the B cell comprises the recombinant nucleic acid molecule encoding the inducible MYC and the recombinant nucleic acid molecule encoding the antigen;
d) culturing the B cell overexpressing MYC under conditions in which MYC overexpression is maintained; and
e) recovering the antibody from the B cell culture.
2. The method of claim 1 , wherein the antigen comprises a human antigen.
3. The method of claim 1 , wherein the inducible MYC is MYC-ER.
4. The method of claim 3 , wherein MYC-ER is induced by 4-hydroxytamoxyfen (4OHT).
5. The method of claim 1 , wherein the B-cell overexpressing MYC is recovered from the spleen or a lymph node.
6. The method of claim 1 , wherein the hematopoietic stem cell is a human hematopoietic stem cell.
7. The method of claim 6 , wherein the antibody is a human antibody.
8. The method of claim 1 , wherein the antigen is selected from the group consisting of a viral antigen, a fungal antigen, a bacterial antigen, a helminth antigen, a parasitic antigen, an ectoparasite antigen, a protozoan antigen, an antigen associated with a disease, and an antigen associated with a condition.
9. The method of claim 1 , wherein the antigen is selected from the group consisting of a protein, a peptide, a cellular receptor, and carbohydrate.
10. The method of claim 1 , wherein the antibody is a monoclonal antibody.
11. The method of claim 1 , wherein the hematopoietic stem cell is a transgenic hematopoietic stem cell.
12. The method of claim 1 , wherein the hematopoietic stem cell is a recombinantly transduced hematopoietic stem cell.